Abeona Reports Strong ZEVASKYN Revenue Growth, In-licenses Novel Oncology Asset

summarizeSummary

Abeona Therapeutics reported strong Q1 2026 revenue growth for ZEVASKYN and expanded its pipeline by in-licensing a novel T-cell therapy for prostate cancer, signaling strategic focus and commercial traction.

check_boxKey Events

• Q1 2026 Revenue Growth

  Net product revenue for ZEVASKYN increased to $8.7 million in Q1 2026, up from $2.4 million in Q4 2025, demonstrating commercial traction.

• New Oncology Pipeline Asset

  The company in-licensed ABO-701, a novel engineered T-cell therapy for advanced prostate cancer, for a $7.0 million upfront payment, with an Investigational New Drug (IND) application expected in the second half of 2027.

• ZEVASKYN Commercial Expansion

  The qualified treatment center (QTC) network expanded to six sites, and patient access grew with published coverage policies now in place for 95% of commercially insured U.S. lives.

• Strategic Portfolio Optimization

  Abeona deprioritized its in-house ophthalmology programs to focus resources on ZEVASKYN commercialization and the new ABO-701 oncology program.

auto_awesomeAnalysis

Abeona Therapeutics reported its first-quarter 2026 financial results, highlighting significant commercial momentum for its gene therapy, ZEVASKYN, with a substantial increase in product revenue. The company also made a strategic move by in-licensing ABO-701, a novel engineered T-cell therapy for advanced prostate cancer, involving a $7.0 million upfront payment. This expands their pipeline into a high-value oncology area, while they deprioritize ophthalmology programs to focus resources.